You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 30 NLR (neutrophil lymphocyte ratio) and PLR (platelet lymphocyte ratio) changes as a predictor of eventual treatment failure and death on nivolumab therapy in renal cell carcinoma

Citation Tools

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Biomarkers, immune monitoring, and novel technologies
30 NLR (neutrophil lymphocyte ratio) and PLR (platelet lymphocyte ratio) changes as a predictor of eventual treatment failure and death on nivolumab therapy in renal cell carcinoma

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Basu A, Suri Y, Nandagopal L, et al
30 NLR (neutrophil lymphocyte ratio) and PLR (platelet lymphocyte ratio) changes as a predictor of eventual treatment failure and death on nivolumab therapy in renal cell carcinoma
Journal for ImmunoTherapy of Cancer 2020;8:doi: 10.1136/jitc-2020-SITC2020.0030